Evidence map›Paper›PMID 40726621›Full record

ArticleJournal of hepatocellular carcinoma2025

A Summary of the HCC-CARE Symposium: Collaborative Approaches to Reaching Equity in Hepatocellular Carcinoma in Boston by 2030.

Kelsey S Lau-Min, Thomas Abrams, Andrea Bullock, Alyson Kaplan, Leslie Salas Karnes, Mark W Kennedy, Christina A LeBedis, Ming V Lin, Nadine Jackson McCleary, Shirin Sioshansi and 5 more

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kelsey S Lau-MinDivision of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Thomas AbramsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrea BullockDepartment of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Alyson KaplanAbdominal Transplant Institute, Tufts Medical Center, Boston, MA, USA.
Leslie Salas KarnesDepartment of Clinical Health Affairs, Massachusetts League of Community Health Centers, Boston, MA, USA.
Mark W KennedyBoston Public Health Commission, Boston, MA, USA.
Christina A LeBedisDepartment of Radiology, Boston Medical Center, Boston, MA, USA.
Ming V LinDepartment of Surgery, Lahey Hospital and Medical Center, Burlington, MA, USA.
Nadine Jackson McClearyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shirin SioshansiDepartment of Radiation Oncology, UMass Memorial Medical Center, Worcester, MA, USA.
Emma VolignyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Elizabeth Paige WalshDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Christopher R ManzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-0928-3492
HCC-CARE
Group authorship list

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality in the United States. Disparities in HCC incidence and mortality are amplified in Boston, Massachusetts, which has 42% higher HCC mortality than the nation. HCC-CARE was a one-day symposium that aimed to identify goals and strategies necessary to eliminate HCC disparities in the Greater Boston area by 2030. Sixty-six local and state stakeholders attended the symposium, including HCC clinical experts (eg, medical oncologists) and primary care clinicians representing all seven of Boston's major cancer centers, ancillary staff members (eg, social workers) and state and local government agencies. The symposium included introductory sessions on HCC disparities, conceptual approaches to addressing disparities, and perspectives of local stakeholders on HCC disparities, followed by two interactive workshops where nine groups brainstormed and voted on goals, then developed preliminary action plans. Symposium participants identified four priority goals and developed associated action plans to eliminate HCC disparities by 2030: 1) improving HCC screening rates to enable early detection, 2) employing community engagement and outreach to communities at high risk of HCC, 3) developing a multi-institutional HCC registry to inform care delivery improvements, and 4) connecting patients with HCC to support services to address common barriers to care. A fifth priority around addressing disparities in HCC treatment emerged from post-symposium feedback. HCC-CARE established a knowledge base and raised the saliency of HCC disparities among participants, created a multi-institutional consortium of individuals committed to addressing HCC disparities, and leveraged the wide-ranging expertise of the participants to identify key goals and strategies for achieving equity in HCC outcomes by 2030. These strategies require further development and implementation through multi-institutional committees established after the symposium for each priority area. The Symposium represented a key first step in launching coordinated efforts to reduce HCC disparities that other cities may emulate.

Indexed as

health equityhepatocellular carcinoma

Identifiers

PMID40726621
PMCPMC12301847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.